Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 3132063, 8 pages
https://doi.org/10.1155/2017/3132063
Research Article

Platelet Carbonic Anhydrase II, a Forgotten Enzyme, May Be Responsible for Aspirin Resistance

1Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw Medical University, Wroclaw, Poland
2Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warszawa, Poland
3Division of Respiratory, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

Correspondence should be addressed to A. Doroszko

Received 22 June 2017; Revised 22 August 2017; Accepted 6 September 2017; Published 27 September 2017

Academic Editor: Valentina Pallottini

Copyright © 2017 M. Jakubowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Writing Group Members, D. Mozaffarian, E. J. Benjamin et al., “Heart disease and stroke statistics-2016 update: a report from the American Heart Association,” Circulation, vol. 133, pp. e38–e360, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Du, Q. Lin, and J. Wang, “A brief review on the mechanisms of aspirin resistance,” International Journal of Cardiology, vol. 220, pp. 21–26, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. U. S. Tantry, M. Gesheff, F. Liu, K. P. Bliden, and P. A. Gurbel, “Resistance to antiplatelet drugs: what progress has been made?” Expert Opinion on Pharmacotherapy, vol. 15, pp. 2553–2564, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. C. N. Floyd and A. Ferro, “Mechanisms of aspirin resistance,” Pharmacology & Therapeutics, vol. 141, pp. 69–78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. M. D. Mijajlovic, O. Shulga, S. Bloch, N. Covickovic-Sternic, V. Aleksic, and N. M. Bornstein, “Clinical consequences of aspirin and clopidogrel resistance: an overview,” Acta Neurologica Scandinavica, vol. 128, pp. 213–219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. G. Kovács, E. Katona, Z. Bereczky et al., “New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals,” Thrombosis Research, vol. 131, pp. 320–324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Homoródi, E. G. Kovács, S. Leé et al., “The lack of aspirin resistance in patients with coronary artery disease,” Journal of Translational Medicine, vol. 14, p. 74, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Evangelista, S. Manarini, A. Di Santo et al., “De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin,” Circulation Research, vol. 98, pp. 593–595, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Voora, T. L. Ortel, J. E. Lucas, J. T. Chi, R. C. Becker, and G. S. Ginsburg, “Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy,” Journal of Thrombosis and Thrombolysis, vol. 33, pp. 246–257, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Voora, D. Cyr, J. Lucas et al., “Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events,” Journal of the American College of Cardiology, vol. 62, pp. 1267–1276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Massimi, R. Guerriero, L. V. Lotti et al., “Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets,” British Journal of Clinical Pharmacology, vol. 78, pp. 1343–1353, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Massimi, A. Ciuffetta, F. Temperilli et al., “Multidrug resistance protein-4 influences aspirin toxicity in human cell line,” Mediators of Inflammation, vol. 2015, Article ID 607957, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Massimi, L. V. Lotti, F. Temperilli et al., “Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment,” Thrombosis and Haemostasis, vol. 116, pp. 1100–1110, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Temperilli, M. Di Franco, I. Massimi et al., “Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and multidrug resistance protein 4 expression in human platelets,” Vascular Pharmacology, vol. 76, pp. 11–17, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. C. N. Floyd, T. Goodman, S. Becker et al., “Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects,” British Journal of Clinical Pharmacology, vol. 78, pp. 320–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Mikula, P. Gaj, K. Dzwonek et al., “Comprehensive analysis of the palindromic motif TCTCGCGAGA: a regulatory element of the HNRNPK promoter,” DNA Research, vol. 17, pp. 245–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bakun, G. Senatorski, T. Rubel et al., “Urine proteomes of healthy aging humans reveal extracellular matrix (ECM) alterations and immune system dysfunction,” Age, vol. 36, pp. 299–311, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Malinowska, M. Kistowski, M. Bakun et al., “Diffprot—software for non-parametric statistical analysis of differential proteomics data,” Journal of Proteomics, vol. 75, pp. 4062–4073, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Doroszko, E. Szahidewicz-Krupska, A. Janus et al., “Endothelial dysfunction in young healthy men is associated with aspirin resistance,” Vascular Pharmacology, vol. 67-69, pp. 30–37, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Siffert and G. Gros, “Carbonic anhydrase in human platelets,” The Biochemical Journal, vol. 217, pp. 727–730, 1984. View at Publisher · View at Google Scholar
  21. F. Belloni and R. Turpini, “Presence of carbonic anhydrase in human platelets,” Haematologica, vol. 42, pp. 217–225, 1957. View at Google Scholar
  22. H. Vaitkevicius, I. Turner, A. Spalding, and W. Lockette, “Chloride increases adrenergic receptor-mediated platelet and vascular responses,” American Journal of Hypertension, vol. 15, pp. 492–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. E. K. Novak, H. O. Sweet, M. Prochazka et al., “Cocoa: a new mouse model for platelet storage pool deficiency,” British Journal of Haematology, vol. 69, pp. 371–378, 1988. View at Publisher · View at Google Scholar
  24. I. A. Brewis and P. Brennan, “Proteomics technologies for the global identification and quantification of proteins,” Advances in Protein Chemistry and Structural Biology, vol. 80, pp. 1–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Peng and S. P. Gygi, “Proteomics: the move to mixtures,” Journal of Mass Spectrometry, vol. 36, pp. 1083–1091, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Temperini, A. Scozzafava, and C. T. Supuran, “Carbonic anhydrase activation and the drug design,” Current Pharmaceutical Design, vol. 14, pp. 708–715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Woodman, C. Brown, and W. Lockette, “Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis,” Hypertension, vol. 56, pp. 463–470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Spalding, H. Vaitkevicius, S. Dill, S. MacKenzie, A. Schmaier, and W. Lockette, “Mechanism of epinephrine-induced platelet aggregation,” Hypertension, vol. 31, pp. 603–607, 1998. View at Publisher · View at Google Scholar
  29. W. Siffert, G. Fox, and G. Gros, “Carbonic anhydrase in human platelets: effects of carbonic anhydrase inhibition on platelet aggregation,” Annals of the New York Academy of Sciences, vol. 429, pp. 207–209, 1984. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Siffert, G. Fox, and G. Gros, “The effect of carbonic anhydrase inhibition on the velocity of thrombin-stimulated platelet aggregation under physiological conditions,” Biochemical and Biophysical Research Communications, vol. 121, pp. 266–270, 1984. View at Publisher · View at Google Scholar · View at Scopus
  31. R. H. Olde Engberink, W. J. Frenkel, B. van den Bogaard, L. M. Brewster, L. Vogt, and B. J. van den Born, “Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis,” Hypertension, vol. 65, pp. 1033–1040, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Shen, W. Herzog, M. Drolet et al., “Aspirin resistance in healthy drug-naive men versus women (from the heredity and phenotype intervention heart study),” The American Journal of Cardiology, vol. 104, pp. 606–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. L. Chang, S. H. Hung, W. Ling, H. C. Lin, H. C. Li, and S. D. Chung, “Association between ischemic stroke and iron-deficiency anemia: a population-based study,” PLoS One, vol. 8, article e82952, 2013. View at Publisher · View at Google Scholar · View at Scopus